Lebwohl David
EVP, Chief Medical Officer at NTLA
- Sold, on record
- $2.4M
- Dollars the filings state
- Form 4 sales
- 10
- Latest Jan 5, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- NTLAIntellia Therapeutics, Inc.EVP, Chief Medical Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale NTLAUnusualSep 21, 2021 2021
Sold 2,400 shares at $149.81 ($360k)
Lebwohl David, EVP, Chief Medical Officer
Sold 75.2% of holdings ($478k position)791 shares leftFiling
- 2 Form 4 sale NTLAPlan not statedOct 14, 2021 +23 days
Sold 2,400 shares at $128.44 ($308k)
Lebwohl David, EVP, Chief Medical Officer
Sold 21.6% of holdings ($1.4M position)8,714 shares left1x usual sizeFiling
- 3 Form 4 sale NTLAPlan not statedNov 5, 2021 +22 days
Sold 2,400 shares at $132.72 ($319k)
Lebwohl David, EVP, Chief Medical Officer
Sold 21.6% of holdings ($1.5M position)8,714 shares left1x usual sizeFiling
- 4 Form 4 sale NTLAPlan not statedJan 1, 2022 +57 days
Sold 1,051 shares at $112.24 ($118k)
Lebwohl David, EVP, Chief Medical Officer
Sold 8.8% of holdings ($1.3M position)10,922 shares left0.4x usual sizeFiling
- 5 Form 4 sale NTLAPlan not statedJan 4, 2023 +368 days
Sold 2,574 shares at $37.21 ($96k)
Lebwohl David, EVP, Chief Medical Officer
Sold 9.1% of holdings ($1.1M position)25,687 shares left1.1x usual sizeFiling
- 6 Form 4 sale NTLANo planJan 3, 2024 +364 days
Sold 5,843 shares at $29.46 ($172k)
Lebwohl David, EVP, Chief Medical Officer
No 10b5-1 planSold 9.7% of holdings ($1.8M position)54,372 shares leftFiling
- 7 Form 4 sale NTLANo planJan 3, 2025 +366 days
Sold 9,557 shares at $12.18 ($116k)
Lebwohl David, EVP, Chief Medical Officer
No 10b5-1 planSold 9.8% of holdings ($1.2M position)87,666 shares leftFiling
- 8 Form 4 sale NTLANo planJan 5, 2026 +367 days
Sold 11,903 shares at $9.21 ($110k)
Lebwohl David, EVP, Chief Medical Officer
No 10b5-1 planSold 8.9% of holdings ($1.2M position)121,249 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (10)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Jan 7, 2026 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 11,903 | $110k | 8.9% | No plan | SEC |
| Jan 3, 2025 | Jan 7, 2025 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 9,557 | $116k | 9.8% | No plan | SEC |
| Jan 3, 2024 | Jan 5, 2024 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 5,843 | $172k | 9.7% | No plan | SEC |
| Jan 4, 2023 | Jan 6, 2023 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 2,574 | $96k | 9.1% | Plan not stated | SEC |
| Jan 1, 2022 | Mar 3, 2022 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 1,051 | $118k | 8.8% | Plan not stated | SEC |
| Nov 5, 2021 | Nov 9, 2021 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 2,400 | $319k | 21.6% | Plan not stated | SEC |
| Oct 14, 2021 | Oct 15, 2021 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 2,400 | $308k | 21.6% | Plan not stated | SEC |
| Sep 21, 2021 | Sep 23, 2021 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 2,400 | $360k | 75.2% | Unusual | SEC |
| Aug 30, 2021 | Sep 1, 2021 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 2,400 | $379k | 75.2% | Unusual | SEC |
| Aug 9, 2021 | Aug 11, 2021 | NTLA | EVP, Chief Medical Officer | Form 4 sale | 2,400 | $394k | 75.2% | Unusual | SEC |